Dr Chirag A. Shah highlights novel emerging treatments in ovarian cancer and provides advice for community oncologists.
Chirag A. Shah, MD
Advertisement
Articles by Chirag A. Shah, MD
Chirag A. Shah, MD, details his personal clinical experience with using niraparib for ovarian cancer maintenance therapies.
An expert shares data from several clinical trials on the use of PARP inhibitors for maintenance therapies in ovarian cancer.
Dr Chirag A. Shah explains the front-line treatment options for ovarian cancer and the factors considered in choosing maintenance therapies.
A gynecologic oncologist discusses the importance of molecular testing in ovarian cancer and how it influences treatment selection.
Chirag A. Shah, MD, presents and reviews the case of a 59-year-old woman with ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
